First Page | Document Content | |
---|---|---|
![]() Date: 2009-10-14 12:19:27Pharmaceuticals policy Biosimilar Biotechnology Drugs Generic drug Food and Drug Administration Test data exclusivity Evergreening Biologic Pharmaceutical sciences Pharmacology Clinical research | Source URL: www.healthlawyers.orgDownload Document from Source WebsiteFile Size: 102,78 KBShare Document on Facebook |
![]() | Working Paper Series NoFIRST-MOVER ADVANTAGES BEFORE AND AFTER TRIPS Evidence from the Indian Pharmaceutical Industry Ajay BhaskarabhatlaDocID: 1p6Uw - View Document |
![]() | PDF DocumentDocID: 1fWv5 - View Document |
![]() | Submission to the Department of Foreign Affairs and Trade: The Trans Pacific Partnership Agreement, Intellectual Property and Medicines 1 October, 2013DocID: 18yKo - View Document |
![]() | Entecavir and Hepatitis B Background on Hepatitis B Hepatitis B virus (HBV) is highly endemic in South Africa and across sub-Saharan Africa, where around 8% of people are chronically infected, and rates of HBV-related liDocID: 18mXH - View Document |
![]() | Australia and New Zealand Health Policy BioMed Central Open AccessDocID: 187up - View Document |